Print

Achillion Pharmaceuticals, Inc. (ACHN) Provides Update on Clinical HCV Development Programs  
11/12/2012 7:48:01 AM

NEW HAVEN, Conn., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today provided an update on the sovaprevir and ACH-3102 clinical development programs and announced new Phase 1b clinical trial results on ACH-2684.
//-->